Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6174442 | VIFOR FRESENIUS | Adsorbent for phosphate from an aqueous medium, production and use of said adsorbent |
Jun, 2020
(3 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10925897 | VIFOR FRESENIUS | Pharmaceutical compositions |
Nov, 2028
(4 years from now) | |
US11013762 | VIFOR FRESENIUS | Pharmaceutical compositions |
Nov, 2028
(4 years from now) | |
US10933090 | VIFOR FRESENIUS | Pharmaceutical compositions |
Nov, 2028
(4 years from now) | |
US10695367 | VIFOR FRESENIUS | Pharmaceutical compositions |
Nov, 2028
(4 years from now) | |
US10925896 | VIFOR FRESENIUS | Pharmaceutical compositions |
Nov, 2028
(4 years from now) | |
US10682376 | VIFOR FRESENIUS | Pharmaceutical compositions |
Nov, 2028
(4 years from now) | |
US11013761 | VIFOR FRESENIUS | Pharmaceutical compositions |
Nov, 2028
(4 years from now) | |
US10925896 (Pediatric) | VIFOR FRESENIUS | Pharmaceutical compositions |
May, 2029
(5 years from now) | |
US11013762 (Pediatric) | VIFOR FRESENIUS | Pharmaceutical compositions |
May, 2029
(5 years from now) | |
US10925897 (Pediatric) | VIFOR FRESENIUS | Pharmaceutical compositions |
May, 2029
(5 years from now) | |
US10933090 (Pediatric) | VIFOR FRESENIUS | Pharmaceutical compositions |
May, 2029
(5 years from now) | |
US10682376 (Pediatric) | VIFOR FRESENIUS | Pharmaceutical compositions |
May, 2029
(5 years from now) | |
US11013761 (Pediatric) | VIFOR FRESENIUS | Pharmaceutical compositions |
May, 2029
(5 years from now) | |
US10695367 (Pediatric) | VIFOR FRESENIUS | Pharmaceutical compositions |
May, 2029
(5 years from now) | |
US9561251 | VIFOR FRESENIUS | Pharmaceutical compositions |
Jan, 2030
(5 years from now) | |
US9561251 (Pediatric) | VIFOR FRESENIUS | Pharmaceutical compositions |
Jul, 2030
(6 years from now) | |
US10624855 | VIFOR FRESENIUS | Pharmaceutical composition, comprising phosphate binder particles |
Nov, 2034
(10 years from now) | |
US11446252 | VIFOR FRESENIUS | Pharmaceutical composition, comprising phosphate binder particles |
Nov, 2034
(10 years from now) | |
US11234938 | VIFOR FRESENIUS | Pharmaceutical composition, comprising phosphate binder particles |
Nov, 2034
(10 years from now) | |
US10624855 (Pediatric) | VIFOR FRESENIUS | Pharmaceutical composition, comprising phosphate binder particles |
May, 2035
(11 years from now) | |
US11446252 (Pediatric) | VIFOR FRESENIUS | Pharmaceutical composition, comprising phosphate binder particles |
May, 2035
(11 years from now) | |
US11234938 (Pediatric) | VIFOR FRESENIUS | Pharmaceutical composition, comprising phosphate binder particles |
May, 2035
(11 years from now) |
Velphoro is owned by Vifor Fresenius.
Velphoro contains Ferric Oxyhydroxide.
Velphoro has a total of 23 drug patents out of which 1 drug patent has expired.
Expired drug patents of Velphoro are:
Velphoro was authorised for market use on 27 November, 2013.
Velphoro is available in tablet, chewable;oral dosage forms.
Velphoro can be used as control of phosphorous levels in patients.
The generics of Velphoro are possible to be released after 26 May, 2035.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Nov 27, 2016 |
Drugs and Companies using FERRIC OXYHYDROXIDE ingredient
Market Authorisation Date: 27 November, 2013
Treatment: Control of phosphorous levels in patients
Dosage: TABLET, CHEWABLE;ORAL